Results 51 to 60 of about 85,285 (279)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Frontiers in Pharmacology, 2022
Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus.
Chen Li, Chen Li, Jie Luo, Jie Luo, Mingyan Jiang, Mingyan Jiang, Keke Wang, Keke Wang   +7 more
doaj   +1 more source

Lactate-proton co-transport and its contribution to interstitial acidification during hypoxia in isolated rat spinal roots [PDF]

, 1993
Exposure of nervous tissue to hypoxia results in interstitial acidification. There is evidence for concomitant decrease in extracellular pH to the increase in tissue lactate.
Aronson, Assaf, Ballanyi, Beaudry, Bonanno, Cabantchik, Chester, Combs, de Hemptinne, Deuticke, Deuticke, Dubinsky, Edlund, Grinstein, Halestrap, Halestrap, Halestrap, Halestrap, Halestrap, Hansen, Imai, Johnson, Juel, Kraig, Krnjević, Kuhr, Marrannes, Mason, Mutch, Poole, Poole, Poole, Poole, Raley-Susman, Roos, Roth, Scheller, Schneider, Schneider, Smith, Spencer, Strupp, Trosper, Walsh, Walz, Walz   +45 more
core   +1 more source

Research Models for Studying Vascular Calcification [PDF]

, 2020
Calcification of the vessel wall contributes to high cardiovascular morbidity and mortality. Vascular calcification (VC) is a systemic disease with multifaceted contributing and inhibiting factors in an actively regulated process.
Babic, Milen, Giet, Markus van der, Herrmann, Jaqueline, Schuchardt, Mirjam, Tölle, Markus   +4 more
core   +1 more source

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes

Journal of Education, Health and Sport, 2022
Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski, Karolina Raksa, Ewelina Powroźniak, Karol Spozowski   +3 more
doaj   +1 more source

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance

ESC Heart Failure, 2022
Aims Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and ‘de novo’ acute heart failure (AHF) continue to experience unacceptably high post ...
João Pedro Ferreira, Joana Pimenta, Brenda Moura, Carlos Aguiar, Fátima Franco   +4 more
doaj   +1 more source

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Turkish Journal of Internal Medicine, 2021
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu, Muhammed Erkam Sencar, İlknur Öztürk Ünsal, Hayri Bostan, Erman Çakal   +4 more
doaj   +1 more source

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

ESC Heart Failure, 2022
Aims Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).
Muhammad Shariq Usman, Muhammad Shahzeb Khan, Gregg C. Fonarow, Stephen J. Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos Filippatos, Andrew J. Stewart Coats, Stefan D. Anker, Javed Butler   +9 more
doaj   +1 more source

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients

Cardiology Journal, 2023
Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica, Aldona Kubica, Klaudyna Grzelakowska, Wioleta Stolarek, Zofia Grąbczewska, Piotr Michalski, Piotr Niezgoda, Stanisław Bartuś, Andrzej Budaj, Mariusz Dąbrowski, Jarosław Drożdż, Ryszard Gellert, Miłosz J. Jaguszewski, Piotr Jankowski, Jacek Legutko, Maciej Lesiak, Przemysław Leszek, Jolanta Małyszko, Przemysław Mitkowski, Jadwiga Nessler, Krzysztof Pawlaczyk, Jolanta Siller-Matula, Tomasz Stompór, Bogumił Wolnik, Eliano Pio Navarese   +24 more
doaj   +1 more source

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors

International Journal of Molecular Sciences, 2022
Several recent cardiovascular trials of SGLT 2 (sodium-glucose cotransporter 2) inhibitors revealed that they could reduce adverse cardiovascular events in patients with T2DM (type 2 diabetes mellitus). However, the exact molecular mechanism underlying the beneficial effects that SGLT2 inhibitors have on the cardiovascular system is still unknown.
Siarhei A. Dabravolski, Alexander D. Zhuravlev, Andrey G. Kartuesov, Evgeny E. Borisov, Vasily N. Sukhorukov, Alexander N. Orekhov   +5 more
openaire   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source